Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 17/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400931 | 0.85 | UTS2R (0.49) | UTS2RMCHR1MEN1LMNAMAPT | |
| SCHEMBL2476829 | 0.84 | UTS2R (0.49) | UTS2RMEN1LMNAMAPTKMT2A | |
| SCHEMBL1482534 | 0.76 | UTS2R (0.53) | UTS2RMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL3230138 | 0.76 | UTS2R (0.47) | UTS2R | |
| SCHEMBL3830929 | 0.74 | UTS2R (0.51) | UTS2RMEN1LMNAKMT2A | |
| SCHEMBL2473252 | 0.74 | HDAC1 (0.47) | UTS2RMEN1LMNAMAPTKMT2A | |
| SCHEMBL2474013 | 0.72 | ROCK2 (0.51) | MEN1KMT2ASMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL3829596 | 0.72 | UTS2R (0.47) | UTS2R | |
| SCHEMBL2474402 | 0.71 | UTS2R (0.47) | UTS2R | |
| SCHEMBL2474114 | 0.71 | UTS2R (0.54) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | UTS2R 11/4885MCHR1 2116/4885MEN1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.